A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Official Title
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Conditions
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intervention / Treatment
Drug: Nadofaragene Firadenovec
Other Study ID Numbers
- 000423
- U1111-1284-0685 (Other Identifier) (OTHER: World Health Organization (UTN))
Learn more at: https://clinicaltrials.gov/study/NCT06510374?term=NCT06510374&rank=1